BOOK
Drug Hypersensitivity and Desensitizations, An Issue of Immunology and Allergy Clinics of North America, E-Book
(2017)
Additional Information
Book Details
Abstract
This issue of Immunology and Allergy Clinics, guest edited by Mariana Castells, is devoted to Drug Hypersensitivity and Desensitizations. Articles in this issue include: Principles and Practice of Drug Desensitization; Incidence and Prevalence of Drug Hypersensitivity; Drug-Induced Anaphylaxis; Penicillin and Beta Lactam Hypersensitivity; Platins Chemotherapy Hypersensitivity: Prevalence and Management; Monoclonal Antibodies Hypersensitivity: Prevalence and Management; Injectable Drugs and MoAbs Reactions and Management with Desensitization; Delayed Cutaneous Reactions to Antibiotics, Management with Desensitization; Management of Children with Hypersensitivity to Antibiotics and MoAbs; Taxenes Hypersensitivity and Management; Progesterone Autoimmune Dermatitis; Severe Delayed Drug Reaction: Role of Genetics and Viral Infections; andAspirin and NSAIDS Hypersensitivity and Management.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Drug Hypersensitivityand Desensitizations\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Erratum | vii | ||
| Foreword: Drug Hypersensitivity: Broadening Horizonsxv | vii | ||
| Preface: Drug Hypersensitivity and Desensitizationsxvii | vii | ||
| Drug-Induced Anaphylaxis629 | vii | ||
| Penicillin and Beta-Lactam Hypersensitivity643 | vii | ||
| Platinum Chemotherapy Hypersensitivity: Prevalence and Management663 | vii | ||
| Management of Hypersensitivity Reactions to Taxanes679 | viii | ||
| Monoclonal Antibodies Hypersensitivity: Prevalence and Management695 | viii | ||
| Management of Children with Hypersensitivity to Antibiotics and Monoclonal Antibodies713 | viii | ||
| Aspirin and Nonsteroidal Antiinflammatory Drugs Hypersensitivity and Management727 | viii | ||
| Delayed Cutaneous Hypersensitivity Reactions to Antibiotics: Management with Desensitization751 | ix | ||
| Subcutaneous Injectable Drugs Hypersensitivity and Desensitization: Insulin and Monoclonal Antibodies761 | ix | ||
| Progestogen Hypersensitivity: An Evidence-Based Approach to Diagnosis and Management in Clinical Practice773 | ix | ||
| Severe Delayed Drug Reactions: Role of Genetics and Viral Infections785 | ix | ||
| IMMUNOLOGYAND ALLERGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| February 2018 | xi | ||
| May 2018 | xi | ||
| August 2018 | xi | ||
| RECENT ISSUES | xi | ||
| August 2017 | xi | ||
| May 2017 | xi | ||
| February 2017 | xi | ||
| Erratum | xiii | ||
| Foreword\r | xv | ||
| Drug Hypersensitivity: Broadening Horizons | xv | ||
| Preface\r | xvii | ||
| Drug Hypersensitivity and Desensitizations | xvii | ||
| Drug-Induced Anaphylaxis | 629 | ||
| Key points | 629 | ||
| INTRODUCTION | 629 | ||
| EPIDEMIOLOGY | 630 | ||
| MECHANISMS INVOLVED IN DRUG-INDUCED ANAPHYLAXIS | 631 | ||
| DIAGNOSIS | 634 | ||
| Anaphylaxis | 634 | ||
| Etiologic Agent | 634 | ||
| MANAGEMENT | 636 | ||
| Anaphylactic Reaction | 636 | ||
| Follow-up | 637 | ||
| SUMMARY | 637 | ||
| REFERENCES | 638 | ||
| Penicillin and Beta-Lactam Hypersensitivity | 643 | ||
| Key points | 643 | ||
| PENICILLIN ALLERGY | 643 | ||
| Background | 643 | ||
| Epidemiology | 644 | ||
| Detriment of “Penicillin Allergy” Label | 644 | ||
| Immunochemistry | 644 | ||
| Penicillin Skin Test Reagents | 645 | ||
| Skin Testing Predictive Value | 646 | ||
| In Vitro Testing | 646 | ||
| Clinical Management | 646 | ||
| Role of history taking | 646 | ||
| Are the symptoms consistent with a possible IgE-related mechanism? | 646 | ||
| Are the symptoms consistent with a severe non–IgE-mediated mechanism? | 647 | ||
| Is the reaction history unclear or not compatible with a possible allergy? | 647 | ||
| When to evaluate | 647 | ||
| Skin Testing | 647 | ||
| Challenge | 648 | ||
| Desensitization | 648 | ||
| Benefit of evaluation | 648 | ||
| Resensitization | 649 | ||
| ALLERGIC CROSS-REACTIVITY BETWEEN PENICILLINS AND OTHER BETA-LACTAM ANTIBIOTICS | 649 | ||
| Penicillin/Cephalosporins | 649 | ||
| Penicillins/Carbapenems | 653 | ||
| Penicillins/Monobactams | 653 | ||
| ALLERGY TO CEPHALOSPORINS | 654 | ||
| REFERENCES | 655 | ||
| Platinum Chemotherapy Hypersensitivity | 663 | ||
| Key points | 663 | ||
| INTRODUCTION | 663 | ||
| BACKGROUND AND EPIDEMIOLOGY | 664 | ||
| MECHANISMS AND CLINICAL PRESENTATION | 665 | ||
| DIAGNOSTIC TESTING | 665 | ||
| Carboplatin Skin Testing | 665 | ||
| Cisplatin Skin Testing | 668 | ||
| Oxaliplatin Skin Testing | 668 | ||
| Specific IgE | 668 | ||
| Basophil Activation Test | 669 | ||
| RISK STRATIFICATION AND DESENSITIZATION | 669 | ||
| Carboplatin | 669 | ||
| Predictive values before hypersensitivity reaction | 669 | ||
| Predictive values after hypersensitivity reaction: utilization for risk stratification with desensitization | 670 | ||
| Cisplatin | 670 | ||
| Oxaliplatin | 670 | ||
| Desensitization Protocols Based on Risk Stratification | 671 | ||
| Cross-Reactivity Between Platinum Agents | 671 | ||
| SUMMARY | 674 | ||
| REFERENCES | 674 | ||
| Management of Hypersensitivity Reactions to Taxanes | 679 | ||
| Key points | 679 | ||
| INTRODUCTION | 679 | ||
| TERMINOLOGY | 680 | ||
| EPIDEMIOLOGY | 680 | ||
| Paclitaxel | 680 | ||
| Docetaxel | 680 | ||
| Nab-Paclitaxel | 680 | ||
| Cabazitaxel | 682 | ||
| PATHOPHYSIOLOGY | 682 | ||
| CLINICAL FEATURES | 682 | ||
| Immediate Hypersensitivity Reactions | 682 | ||
| Nonimmediate Hypersensitivity Reactions | 682 | ||
| DIAGNOSTIC TESTS | 683 | ||
| Tryptase | 683 | ||
| Skin Testing | 683 | ||
| DIFFERENTIAL DIAGNOSIS | 684 | ||
| RE-EXPOSURE TO TAXANES AFTER A HYPERSENSITIVITY REACTION | 684 | ||
| DESENSITIZATION PROTOCOLS AND PREMEDICATION | 685 | ||
| CHALLENGE PROCEDURE | 689 | ||
| CURRENT CONTROVERSIES | 689 | ||
| SUMMARY | 690 | ||
| REFERENCES | 690 | ||
| Monoclonal Antibodies Hypersensitivity | 695 | ||
| Key points | 695 | ||
| INTRODUCTION | 695 | ||
| PHENOTYPES AND ENDOTYPES | 696 | ||
| Type I Hypersensitivity | 696 | ||
| Immunoglobulin G–Mediated Reactions | 696 | ||
| Type III Hypersensitivity Reactions | 696 | ||
| Type IV Hypersensitivity Reactions | 697 | ||
| Cytokine Storm Reactions | 697 | ||
| Mixed Reactions | 697 | ||
| MONOCLONAL ANTIBODIES | 697 | ||
| Anti–Tumor Necrosis Factor-α | 697 | ||
| Infliximab (Remicade) | 697 | ||
| Etanercept (Enbrel) | 697 | ||
| Adalimumab (Humira) | 697 | ||
| Golimumab (Simponi) | 698 | ||
| Certolizumab pegol (Cimzia) | 698 | ||
| Anti-CD20 | 698 | ||
| Rituximab (Rituxan) | 698 | ||
| Ofatumumab (Arzerra) | 699 | ||
| Obinutuzumab (Gazyva) | 699 | ||
| Anti–Human Epidermal Growth Factor Receptor-2 | 699 | ||
| Trastuzumab (Herceptin) | 699 | ||
| Pertuzumab (Perjeta) | 699 | ||
| Anti–Immunoglobulin E | 700 | ||
| Omalizumab (Xolair) | 700 | ||
| Anti-CD30 | 700 | ||
| Brentuximab vedotin (Adcetris) | 700 | ||
| Anti–Epidermal Growth Factor Receptor | 700 | ||
| Cetuximab (Erbitux) | 700 | ||
| Anti–Vascular Endothelial Growth Factor-A | 700 | ||
| Bevacizumab (Avastin) | 700 | ||
| Anti–Interleukin-6 | 700 | ||
| Tocilizumab (Actemra) | 700 | ||
| Anti–CC Chemokine Receptor 4 | 701 | ||
| Mogamulizumab (Poteligeo) | 701 | ||
| Anti Epithelial Cell Adhesion Molecule/CD3 | 701 | ||
| Catumaxomab (Removab) | 701 | ||
| BIOMARKERS | 701 | ||
| MANAGEMENT | 701 | ||
| Acute Care | 701 | ||
| Rapid Drug Desensitization | 703 | ||
| Rapid Drug Desensitization to Subcutaneous Monoclonal Antibodies | 704 | ||
| Challenge | 706 | ||
| SUMMARY | 706 | ||
| REFERENCES | 706 | ||
| Management of Children with Hypersensitivity to Antibiotics and Monoclonal Antibodies | 713 | ||
| Key points | 713 | ||
| Introduction | 713 | ||
| Epidemiology | 714 | ||
| General principles | 714 | ||
| Risk factors | 716 | ||
| Clinical features | 717 | ||
| Cytokine Release Syndrome | 717 | ||
| Immunoglobulin E-Mediated Reactions | 717 | ||
| IgG-Mediated Reactions | 717 | ||
| Differential diagnosis and cross-reactivity | 718 | ||
| Diagnostic testing | 718 | ||
| Drug challenge and desensitization | 720 | ||
| Future considerations | 721 | ||
| References | 722 | ||
| Aspirin and Nonsteroidal Antiinflammatory Drugs Hypersensitivity and Management | 727 | ||
| Key points | 727 | ||
| INTRODUCTION | 727 | ||
| NONSTEROIDAL ANTIINFLAMMATORY DRUG HYPERSENSITIVITY ENDOTYPES AND MECHANISMS | 728 | ||
| PREVALENCE | 729 | ||
| NONSTEROIDAL ANTIINFLAMMATORY DRUG-EXACERBATED CUTANEOUS DISEASE | 730 | ||
| Clinical Presentation of Nonsteroidal Antiinflammatory Drug-exacerbated Cutaneous Disease | 730 | ||
| Diagnosis of Nonsteroidal Antiinflammatory Drug-exacerbated Cutaneous Disease | 730 | ||
| Controversy | 730 | ||
| Management of Nonsteroidal Antiinflammatory Drug-exacerbated Cutaneous Disease | 731 | ||
| Nonsteroidal Antiinflammatory Drug-exacerbated Cutaneous Disease and the Role of Aspirin Desensitization | 731 | ||
| NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED URTICARIA/ANGIOEDEMA | 732 | ||
| Diagnosis of Nonsteroidal Antiinflammatory Drug-induced Urticaria/Angioedema | 732 | ||
| Management of Nonsteroidal Antiinflammatory Drug-induced Urticaria/Angioedema | 732 | ||
| Aspirin Desensitization in Nonsteroidal Antiinflammatory Drug-Induced Urticaria/Angioedema | 732 | ||
| SINGLE NONSTEROIDAL ANTIINFLAMMATORY DRUG-INDUCED URTICARIA/ANGIOEDEMA, ANAPHYLAXIS, OR BOTH | 732 | ||
| Diagnosis of Single Nonsteroidal Antiinflammatory Drug-Induced Urticaria/Angioedema | 733 | ||
| Management of Single Nonsteroidal Antiinflammatory Drug-Induced Urticaria/Angioedema | 733 | ||
| ASPIRIN-EXACERBATED RESPIRATORY DISEASE | 734 | ||
| Clinical Characteristics | 734 | ||
| Pathogenesis of Aspirin-Exacerbated Respiratory Disease | 735 | ||
| Mast Cells | 735 | ||
| Eosinophils | 736 | ||
| Tissue Remodeling | 736 | ||
| Aspirin Challenges and Diagnosis of Aspirin-Exacerbated Respiratory Disease | 737 | ||
| Aspirin Desensitization for Aspirin-exacerbated Respiratory Disease | 738 | ||
| COX-2 INHIBITORS | 738 | ||
| SALICYLATES | 739 | ||
| CHILDREN | 740 | ||
| Chronic Urticaria | 740 | ||
| Respiratory Reactions | 740 | ||
| COMMON CLINICAL SCENARIOS | 740 | ||
| Emergent Need for Aspirin in Acute Coronary Syndrome | 740 | ||
| Need Assessment of Nonsteroidal Antiinflammatry Drug Hypersensitivity for Pain Management Options | 741 | ||
| SUMMARY | 742 | ||
| REFERENCES | 742 | ||
| Delayed Cutaneous Hypersensitivity Reactions to Antibiotics | 751 | ||
| Key points | 751 | ||
| INTRODUCTION | 751 | ||
| PATHOPHYSIOLOGY | 752 | ||
| MANAGEMENT | 753 | ||
| SUMMARY | 757 | ||
| REFERENCES | 758 | ||
| Subcutaneous Injectable Drugs Hypersensitivity and Desensitization | 761 | ||
| Key points | 761 | ||
| TUMOR NECROSIS FACTOR-α INHIBITORS | 761 | ||
| Etanercept | 762 | ||
| Adalimumab | 762 | ||
| Clinical Presentations of Hypersensitivity Reactions to Etanercept and Adalimumab | 762 | ||
| Underlying Mechanisms and Diagnostic Approach to Local and Systemic Hypersensitivity Reactions to Etanercept and Adalimumab | 762 | ||
| Management of Hypersensitivity Reactions to Tumor Necrosis Factor-α Inhibitors with Desensitization | 764 | ||
| INSULIN | 766 | ||
| Clinical Presentations of Hypersensitivity Reactions to Insulin | 766 | ||
| Diagnostic Approach to Hypersensitivity Reactions to Insulin | 767 | ||
| Management of Hypersensitivity Reactions to Insulin with Desensitization | 767 | ||
| OMALIZUMAB | 768 | ||
| Clinical Presentations of Hypersensitivity Reactions to Omalizumab | 768 | ||
| Diagnostic Approach to Hypersensitivity Reactions to Omalizumab | 768 | ||
| Management of Hypersensitivity Reactions to Omalizumab with Desensitization | 768 | ||
| REFERENCES | 769 | ||
| Progestogen Hypersensitivity | 773 | ||
| Key points | 773 | ||
| INTRODUCTION | 773 | ||
| DEFINITIONS | 774 | ||
| EPIDEMIOLOGY | 774 | ||
| THE CLINICAL ENCOUNTER | 774 | ||
| History | 774 | ||
| Physical | 776 | ||
| DIAGNOSTIC TESTING OPTIONS | 777 | ||
| Skin Testing | 777 | ||
| Progesterone Challenge | 777 | ||
| Patch Testing | 777 | ||
| MANAGEMENT | 778 | ||
| ACTIVE AREAS OF RESEARCH | 780 | ||
| Pathomechanisms of Progestogen Hypersensitivity | 780 | ||
| Advances in Diagnostic Testing | 780 | ||
| Potential Treatment Options | 780 | ||
| SUMMARY | 780 | ||
| REFERENCES | 781 | ||
| Severe Delayed Drug Reactions | 785 | ||
| Key points | 785 | ||
| INTRODUCTION | 785 | ||
| CLINICAL PHENOTYPES OF IMMUNE-MEDIATED ADVERSE DRUG REACTIONS | 786 | ||
| Drug Reaction with Eosinophilia and Systemic Symptoms | 786 | ||
| Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis | 786 | ||
| The Abacavir Hypersensitivity Syndrome | 788 | ||
| Emerging Immune-mediated Adverse Drug Reactions: Immune Checkpoint Inhibitors | 788 | ||
| Clinical Mimics of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis | 788 | ||
| GENETIC ASSOCIATIONS OF IMMUNE-MEDIATED ADVERSE DRUG REACTIONS | 789 | ||
| Human Leukocyte Antigen | 789 | ||
| Drug Metabolism and Transport | 794 | ||
| IMMUNE MECHANISMS OF IMMUNE-MEDIATED ADVERSE DRUG REACTIONS | 795 | ||
| Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis | 797 | ||
| Drug Reaction with Eosinophilia and Systemic Symptoms | 797 | ||
| The Heterologous Immunity Hypothesis as a Model for the Pathogenesis and Risk of Immune-Mediated Adverse Drug Reactions | 798 | ||
| OPPORTUNITIES FOR TRANSLATION INTO THE CLINICAL SETTING | 802 | ||
| SUMMARY AND FUTURE DIRECTIONS | 803 | ||
| REFERENCES | 803 |